INTC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intel Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
Intel Corporation · Technology
$82.54
-5.4% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+28.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
PFE |
| Current Price |
$82.54 |
$26.33 |
| Fair Value Estimate |
$78.09 |
$33.85 |
| Upside to Fair Value |
-5.4%
|
+28.6%
|
| Market Cap |
$414.4B |
$149.8B |
| Forward P/E |
-132.2x
|
19.3x
|
| EV / EBITDA |
50.1x
|
12.9x
|
| Price / Sales |
7.7x
|
2.4x
|
| Price / FCF |
-132.9x
|
16.5x
|
| Revenue Growth YoY |
+7.2%
|
-1.2%
|
| Gross Margin |
35.4%
|
70.3%
|
| Operating Margin |
-9.4%
|
24.7%
|
| Return on Equity |
-3.0%
|
8.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.06%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Intel Corporation is a leading semiconductor company transitioning to a foundry business model while maintaining significant revenue from client computing and data center segments. Despite a strong market position and experienced leadership, the company faces earnings pressure with a 354% decline in earnings in the most recent quarter and negative margins. The stock trades at $82.54, which is 5.4…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
INTC |
PFE |
| Zone Low |
$58.57 |
$25.39 |
| Zone High |
$66.38 |
$28.77 |
| In Buy Zone? |
No
|
Yes
|